Search research articles
Contact Us
Filters
Showing results (181-190 of 227) with videos related to
Page
of 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
JAMA Oncology
|
July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2020
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Miriam Ficial, Opeyemi A Jegede, Miriam Sant'Angelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F McDermott, Charles G Drake, Mario Sznol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
Thomas Denize, Opeyemi A Jegede, Sayed Matar, et al.
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
The Lancet. Oncology
|
June 10, 2016
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K Choueiri, Bernard Escudier, Thomas Powles, et al.
Cancer
|
April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Robert J Motzer, David F McDermott, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Suzanne L Topalian, Mario Sznol, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Nizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 227) with videos related to
Sort By:
Page
of 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
JAMA Oncology
|
July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2020
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Miriam Ficial, Opeyemi A Jegede, Miriam Sant'Angelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F McDermott, Charles G Drake, Mario Sznol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
Thomas Denize, Opeyemi A Jegede, Sayed Matar, et al.
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
The Lancet. Oncology
|
June 10, 2016
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K Choueiri, Bernard Escudier, Thomas Powles, et al.
Cancer
|
April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Robert J Motzer, David F McDermott, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Suzanne L Topalian, Mario Sznol, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Nizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Page
of 23